Full-Time

Clinical Research Physician

Posted on 2/28/2025

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Senior, Expert

Company Does Not Provide H1B Sponsorship

San Antonio, TX, USA + 1 more

More locations: Ambler, PA, USA

Remote anywhere in the U.S.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Biology & Biotech
Required Skills
Data Analysis
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Icon referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Medical degree (MD or equivalent) with relevant clinical research experience.
  • Strong biologics and immunology experience.
  • Strong understanding of clinical trial processes and regulatory requirements.
  • Excellent clinical assessment skills and a commitment to patient safety and ethical research practices.
  • Effective communication and interpersonal skills, with the ability to engage with diverse stakeholders.
  • Demonstrated ability to work collaboratively in a fast-paced, team-oriented environment.
Responsibilities
  • Leading the design and execution of clinical trial protocols, ensuring alignment with scientific and regulatory guidelines.
  • Monitoring patient safety and overseeing the clinical aspects of trials to ensure compliance with GCP standards.
  • Collaborating with cross-functional teams to analyze study data and provide medical insights that guide decision-making.
  • Engaging with investigators and study sites to ensure adherence to protocols and facilitate successful trial execution.
  • Contributing to the preparation of regulatory submissions and clinical study reports.

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon leverages a global network of experts who have experience across various therapeutic areas. This extensive expertise allows them to tailor their solutions to meet the specific needs of their clients, setting them apart from competitors who may not offer the same level of specialized support. The primary goal of Icon is to support the development of life-saving and life-enhancing products efficiently and effectively.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances trial efficiency and participant satisfaction.
  • Increased use of AI in biomarker detection accelerates clinical trial processes.
  • Appointment of Barry Balfe as COO is expected to drive further growth.

What critics are saying

  • Complexity in multi-indication trials may lead to inefficiencies.
  • Securities fraud lawsuit could have significant financial and reputational impacts.
  • Biomarkers' full potential is not yet optimized, hindering research progress.

What makes Icon unique

  • ICON offers a full range of consulting, development, and commercialization services globally.
  • The company focuses on reducing time to market, cost, and increasing quality for clients.
  • ICON's expertise spans a broad range of therapeutic areas, enhancing its service offerings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

PharmiWeb
May 7th, 2025
Global Icon Survey Shows Need For More Efficient Obesity Clinical Trial Design To Realise Full Potential Of Next-Gen Multi-Indication Therapies

Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

PharmiWeb
Mar 4th, 2025
​​Mural Health And Icon Announce Partnership To Enhance Participant And Site Experience In Clinical Trials​

BERWYN, PENNSYLVANIA and DUBLIN, IRELAND, 4 March 2025 - Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link. ICON will ​utilise​ Mural Link’s innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. “From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation,” said Sam Whitaker, CEO of Mural Health. “This partnership represents a shared vision of removing barriers to trial participation​ and advancing participation financial neutrality​, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities.”

INACTIVE